MorphoSys : National Comprehensive Cancer Network® Updates Designation of Monjuvi® (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas - Form 6-K
National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022